Abstract
Psychiatric trials have some of the lowest success rates across therapeutic areas, resulting in decreased investment in psychopharmacological drug development even as the need for more effective treatments grows. Digital measures and digital biomarkers (DBMs) provide one potential avenue for ameliorating three of the largest problems impeding clinical trial success in psychiatry: diagnostic heterogeneity, endpoint subjectivity, and high placebo response rates. First, DBMs may address heterogeneity and comorbidity in psychiatric nosology by identifying predictive DBMs of treatment response via the targeting of drugs to psychiatric subtypes. Second, DBMs can provide objective measures of physiology and behavior that when grounded in meaningful aspects of health (MAH) could support use for regulatory decision-making. By objectively and continuously measuring aspects of a patient's disease that the patient wants to improve or prevent from getting worse, DBMs might provide clinical trial endpoints that are more sensitive to treatment effects as compared to traditional clinician-reported outcomes. Lastly, DBMs could help address challenges surrounding high placebo response rates. Development of predictive DBMs of placebo response may allow for improved enrichment study designs to reduce placebo response. Objective digital measures may also be more robust against the placebo effect and offer an improved study endpoint alternative. Successful deployment of DBMs to address the historical challenges facing psychiatric drug trials will require close collaboration between industry, academic, and regulatory partners.